

* * * * *

The meeting will be webcast at www.fcc.gov/live. Open captioning will be provided as well as a text only version on the FCC website. Other reasonable accommodations for people with disabilities are available upon request. In your request, include a description of the accommodation you will need and a way we can contact you if we need more information. Last minute requests will be accepted but may be impossible to fill. Send an email to: fcc504@fcc.gov or call the Consumer & Governmental Affairs Bureau at 202-418-0530.

Press Access—Members of the news media are welcome to attend the meeting and will be provided reserved seating on a first-come, first-served basis. Following the meeting, the Chairwoman may hold a news conference in which she will take questions from credentialed members of the press in attendance. Also, senior policy and legal staff will be made available to the press in attendance for questions related to the items on the meeting agenda. Commissioners may also choose to hold press conferences. Press may also direct questions to the Office of Media Relations (OMR): MediaRelations@fcc.gov. Questions about credentialing should be directed to OMR.

Additional information concerning this meeting may be obtained from the Office of Media Relations, (202) 418-0500. Audio/Video coverage of the meeting will be broadcast live with open captioning over the internet from the FCC Live web page at www.fcc.gov/live.

Federal Communications Commission.
Dated: December 6, 2023.

Marlene Dortch,
Secretary.

[FR Doc. 2023-27208 Filed 12-11-23; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL ELECTION COMMISSION

Sunshine Act Meetings

TIME AND DATE: Thursday, December 14, 2023, at 10:30 a.m.

PLACE: *Hybrid Meeting:* 1050 First Street NE Washington, DC 12th and Virtual.

Note: For those attending the meeting in person, current COVID-19 safety protocols for visitors, which are based on the CDC COVID-19 hospital admission level in Washington, DC, will be updated on the Commission's contact page by the Monday before the meeting. See the contact page at <https://www.fec.gov/contact/>. If you would like to virtually access the meeting, see the instructions below.

STATUS: This meeting will be open to the public, subject to the above-referenced guidance regarding the COVID-19 hospital admission level and corresponding health and safety procedures. To access the meeting virtually, go to the Commission's website www.fec.gov and click on the banner to be taken to the meeting page.

MATTERS TO BE CONSIDERED:

Draft Advisory Opinion 2023-08:
Cowboy Analytics, LLC
REG 2021-01 (Candidate Salaries)—
Draft Final Rules and Explanation and
Justification
REG 2013-01 (Technological
Modernization)—Draft Final Rules
and Explanation and Justification
Draft Legislative Recommendations
2023
Election of Officers for 2024
Management and Administrative
Matters

CONTACT PERSON FOR MORE INFORMATION:
Judith Ingram, Press Officer, Telephone:
(202) 694-1220.

Individuals who plan to attend in person and who require special assistance, such as sign language interpretation or other reasonable accommodations, should contact Laura E. Sinram, Secretary and Clerk, at (202) 694-1040 or secretary@fec.gov, at least 72 hours prior to the meeting date.

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Laura E. Sinram,
Secretary and Clerk of the Commission.

[FR Doc. 2023-27286 Filed 12-8-23; 4:15 pm]

BILLING CODE 6715-01-P

FEDERAL FINANCIAL INSTITUTIONS EXAMINATION COUNCIL

[Docket No. AS23-20]

Appraisal Subcommittee Notice of Meeting

AGENCY: Appraisal Subcommittee of the Federal Financial Institutions Examination Council.

ACTION: Notice of special closed meeting.

SUMMARY: In accordance with section 1104(b) of title XI of the Financial Institutions Reform, Recovery, and Enforcement Act of 1989, as amended, notice is hereby given that the Appraisal Subcommittee (ASC) met for a Special Closed Meeting on this date.

Location: Virtual meeting via Webex.

Date: December 6, 2023.

Time: 10:00 a.m. ET.

Action and Discussion Item

Personnel Matter

The ASC convened a Special Closed Meeting to discuss a personnel matter. No action was taken by the ASC.

James R. Park,
Executive Director.

[FR Doc. 2023-27152 Filed 12-11-23; 8:45 am]

BILLING CODE 6700-01-P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551-0001, not later than December 27, 2023.

A. Federal Reserve Bank of Kansas City (Jeffrey Imgarten, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri, 64198-0001. Comments can also be sent electronically to KCApplicationComments@kc.frb.org:

1. *Jeff A. Berkley, Lawrence, Kansas, as co-trustee of the H.J. Berkley Trust U/A dated 05/06/69, Salina, Kansas, the Karla J. Spurgeon Trust II, the Karen M. Deckert Trust II, the Calvin J. Berkley Trust II, the Marika Spurgeon GP Trust, the Brenna Spurgeon GP Trust, the Patrick Spurgeon GP Trust, the Samuel Deckert GP Trust, the Lucas Deckert GP Trust, the Megan Berkley GP Trust, and the Collin Berkley GP Trust, all of Tescott, Kansas; Jonathan D. Berkley, Stockton, Kansas, as co-trustee of the*

H.J. Berkley Trust U/A dated 05/06/69, and the Robert B. Berkley Trust U/A dated 12/01/67, both of Salina, Kansas; the Don Berkley Trust No. 2, Don and Patricia Berkley, as co-trustees, all of Abilene, Kansas; the Jerry J. Berkley Trust No. 2, Eleanor A. Berkley and Bruce A. Berkley, as co-trustees, all of Downs, Kansas, and Cheryl L. Jamison, as co-trustee of the aforementioned trust, Emporia, Kansas; the Paul D. Berkley Trust No. 2, Bill Berkley, as co-trustee, both of Downs, Kansas, Brandon Berkley, Denver, Colorado, and Bradley Berkley, Dallas, Texas, as co-trustees of the aforementioned trust; the Robert B. Berkley Family Trust, Lila A. Berkley, as co-trustee, both of Salina, Kansas, Lila Jean Alexander, Houston, Texas, and John A. Berkley, Stockton, Kansas, as co-trustees of the aforementioned trust; the Hal J. Berkley Trust A and the Eleanor L. Berkley Trust, Hal J. Berkley and Eleanor L. Berkley, as co-trustees, all of Tescott, Kansas; the Karla J. Spurgeon Trust II, the Marika Spurgeon GP Trust, the Brenna Spurgeon GP Trust, and the Patrick Spurgeon GP Trust, Karen M. Deckert and Calvin J. Berkley, as co-trustees, all of Tescott, Kansas, and Jeff A. Berkley, as co-trustee; the Karen M. Deckert Trust II, the Samuel Deckert GP Trust, and the Lucas Deckert GP Trust, all of Tescott, Kansas, Karla J. Spurgeon, Lawrence, Kansas, Jeff A. Berkley, and Calvin J. Berkley, as co-trustees; the Jeff A. Berkley Trust II, the Rebekah Berkley GP Trust, and the Rachel Berkley GP Trust, all of Tescott, Kansas, Karla J. Spurgeon, Karen M. Deckert, and Calvin J. Berkley, as co-trustees; the Calvin J. Berkley Trust II, the Megan Berkley GP Trust, and the Collin Berkley GP Trust, all of Tescott, Kansas, Karla J. Spurgeon, Karen M. Deckert, and Jeff A. Berkley as co-trustees; the Paula C. Nelson Trust No. 2, Paula Nelson, as trustee, both of Tescott, Kansas; the Mary Beth Phelps Trust No. 2, Mary Beth Phelps, as trustee, both of Tescott, Kansas; the Mark A. Berkley Trust and the Jane B. Berkley Trust, Mark A. and Jane B. Berkley, as co-trustees, all of Leawood, Kansas; Elizabeth E. Berkley, Naples, Florida, as co-trustee of the Stuart C. Berkley Trust and the Melissa J. Berkley Trust, both of Leawood, Kansas; Stuart C. Berkley, Prairie Village, Kansas, as co-trustee of the Elizabeth E. Berkley Trust and the Melissa J. Berkley Trust, both of Leawood, Kansas; Melissa Ungashick, Overland Park, Kansas, as co-trustee of the Stuart C. Berkley Trust and the Elizabeth E. Berkley Trust; Earl H. Matthews and Burke L. Matthews, both of Salina, Kansas; to join the Berkley Family Group, a group acting in

concert, to retain voting shares of Tescott Bancshares, Inc., and thereby indirectly retain voting shares of The Bank of Tescott, both of Tescott, Kansas.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board.

[FR Doc. 2023-27237 Filed 12-11-23; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data Request on Systematic Review—Interventions To Improve Care of Bereaved Persons

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submission.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on *Systematic Review—Interventions to Improve Care of Bereaved Persons*, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

DATES: *Submission Deadline* on or before January 11, 2024.

ADDRESSES:

Email submissions: epc@ahrq.hhs.gov.

Print submissions:

Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.

Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Kelly Carper, Telephone: 301-427-1656 or Email: epc@ahrq.hhs.gov.

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the

evidence for *Systematic Review—Interventions to Improve Care of Bereaved Persons*. AHRQ is conducting this review pursuant to section 902 of the Public Health Service Act, 42 U.S.C. 299a.

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on *Systematic Review—Interventions to Improve Care of Bereaved Persons*. The entire research protocol is available online at: <https://effectivehealthcare.ahrq.gov/products/bereaved-persons/protocol>.

This is to notify the public that the EPC Program would find the following information on *Systematic Review—Interventions to Improve Care of Bereaved Persons* helpful:

- A list of completed studies that your organization has sponsored for this topic. In the list, please *indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.*

- *For completed studies that do not have results on ClinicalTrials.gov, a summary, including the following elements, if relevant: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.*

- *A list of ongoing studies that your organization has sponsored for this topic.* In the list, please provide the [ClinicalTrials.gov](https://clinicaltrials.gov) trial number or, if the trial is not registered, the protocol for the study including, if relevant, a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

- Description of whether the above studies constitute *ALL Phase II and above clinical trials* sponsored by your organization for this topic and an index outlining the relevant information in each submitted file.

Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on topics not included in